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ABSTRACT

The billion dollar pharmaceutical research and development pipeline suffers
greatly from high attrition rates of novel therapeutic compounds within pre-clinical and
clinical trials. Poor bioavailability in many new drugs, originating in the various
methodologies of high throughput screening, may explain part of these growing failure
rates. One interpretation of this phenomenon relies on bioavailability’s correlation with
aqueous solubility; much modern processing allows chemicals to fully develop without
touching water, yielding upwards of 90% of new chemical entities practically insoluble
in aqueous media. Thus, one approach to alleviating bioavailability and potentially
clinical attrition rates necessitates augmented aqueous solubility. The amorphous
nanoparticle presents the largest boost in aqueous solubility of a chemical through
processing alone.
In this contribution, we propose electrospray as a novel, competitive candidate to
produce pharmaceutical amorphous nanoparticles with the intent of augmenting
solubility. Electrospray represents an idyllic nominee for three reasons: repeatability,
flexibility, and scalability. Electrospray offers low batch to batch variation with less than
30% relative standard deviation between various droplets. This triumphs over the several
orders of magnitude in variation in pneumatic sprays. Electrospray’s flexibility draws
from its ability to attain diameters over several orders of magnitude, ranging from
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hundreds of microns to several nanometers; in this contribution droplets are produced
between 500 𝑛𝑚 and 1 𝜇𝑚. Finally, electrospray displays scalability to any industrial
requirement; though a single nozzle operates at mere microliters per hour, a single
multiplexed array of emitters may increase this throughput by several orders of
magnitude.
This exploration, utilizing Indomethacin as a model low solubility chemical,
verifies electrospray as a compatible processing tool for the pharmaceutical industry.
Scanning electron microscopy coupled with the image analysis software ImageJ gleans
the size and shape of emitted (and dried) particles. Amorphicity verification of particles
employs grazing angle x-ray diffraction. Finally, ultraviolet and visual spectrum
spectroscopy evaluates the solubility advantage of particles.
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CHAPTER 1: BIOAVAILABILITY AND SOLUBILITY

1.1 Pharmaceutical Research and Development Overview
The biopharmaceutical industry grosses over a trillion dollars annually (IMS 2012)
and constantly expands via the discovery of new chemical entities. In order for these new
drugs to become profitable and help people, they must pass FDA clinical trials as well as
a preclinical battery. This process suffers from a substantial attrition rate demonstrated
in Figure 1.

Figure 1: Attrition in the Pharmaceutical R&D Pipeline
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Unfortunately for pharmaceutical developers, this attrition rate is only worsening
with time. The issue is complex but owes some responsibility to screening processes and
their effect on bioavailability.
1.1.1 Screening
Pharmaceutical research and development finds potential drug candidates
through target based screening, phenotypic screening, modification of natural substances
and biologic based approaches (Swinney et al, 2011). Most high potential chemicals come
from the target based and phenotypic screening; these are high throughput,
combinatorial processes. Target based screening allows for rational design of small
molecule. This molecule design process finds chemical groups which react well with a
certain target. Utilizing high throughput chemical libraries, these chemical groups find a
suitable backbone yielding a final product. Phenotypic screening pushes high throughput
screening to its limit; the process combinatorially tests vast libraries of chemicals until
something meets the desired criterion. Since water tends to not facilitate chemical
reactions as rigorously as these screening processes would prefer, dimethyl sulfoxide
(DMSO) or polyethylene glycol (PEG) are almost always used as the solvent
environment. (Babu, 2011) These non-aqueous environments of development can lead to
unpredictable properties when exposed to an aqueous environment (such as the human
body).
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1.1.2 Biopharmaceutical Classification System
The Biopharmaceutical Classification System (BCS), pioneered by Amidon et al.,
specifically outlines how drugs can be classified and the system has been adopted widely
throughout the industry. This system draws two qualifying lines of properties: solubility
and permeability. Solubility, in this context, refers to the ratio between the saturation
limit of a drug in water and the maximally effective dose. A non-dimensional constant is
introduced to represent that number. Permeability is a measure of how well a chemical
will pass through the body’s biological boundaries and is measured by a partitioning
constant. In the current state of biopharmaceutical research, good permeability comes
readily from the screening process but solubility remains an elusive property for the
pharmaceutical industry. With two independent quantities defining these chemicals, four
classes naturally form from the different combinations of high and low solubility and
permeability. Figure 2 demonstrates graphically the BCS and approximate distribution
of current market and research and development drugs (Thayer et al.).
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Figure 2: The BCS and Relative Distribution of Market and Research Drugs

1.1.3 Pharmacodynamics and Pharmacokinetics
Pharmacodynamics is the effect a drug has on the body. Target based screening
focuses solely on the pharmacodynamics of a chemical. Tremendous resources are
allocated in treating a symptom or specific efficacy criterion. Pharmacodynamics drives
the entire innovation process within the pharmaceutical pipeline. Other critical
properties also contribute to the success of a drug in the body.
Pharmacokinetics describes the absorption of the drug into the body, the
distribution of the substance through the body, the metabolization of the chemical into
waste product, and the excretion of those waste products safely out of the body. Those
4

four items constitute the ADME summary of pharmacokinetics. More generally,
pharmacokinetics describes the body’s effect on the drug i.e. how the body’s systems
handle it. Pharmacokinetic properties are determined by a host of factors but among the
most important is the bioavailability of a compound, or the fraction of an administered
dose that reaches the bloodstream. Bioavailability constitutes the first half of the
pharmacokinetic story (absorption and distribution) and determines if and how a drug
will act. Further, bioavailability strongly correlates with the qualities outlined in the BCS,
solubility and permeability. Thus, while phenotypic and target based screening tackle the
problem of pharmacodynamics, it is the solubility and permeability of a compound
which largely indicate the pharmacokinetics.
1.2 Solubility
Because of the screening processes, many NCE products are designed without
much thought into the pharmacokinetics and BCS properties. In fact, the unintended
consequences of the high throughput screening are a shift towards high molecular
weights and increasing lipophilicity. It has been reported that 40% of all marketed drugs
are poorly water soluble. Further, between 70 and 90% of new chemical entities in the
research pipeline suffer from low solubility (Thayer, 2010). It is widely accepted that
tackling solubility issues in these drugs represents one of the largest challenges in drug
development. Finally it is not enough to improve the saturation concentration but also
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boost the dissolution rate since these chemicals have a limited amount of residence time
in the digestive system.
This contribution focuses heavily on the improvement of solubility via processing
of drugs (without chemical manipulation). To accomplish this effectively, parameters of
solubility must be defined. First, the saturation limit of a chemical describes the highest
concentration a solute will dissolve to inside a solution. This saturation limit is dependent
on several things discussed in greater detail below. When boosting the solubility,
supersaturation becomes a critical parameter. Supersaturation describes the ratio of the
current concentration with the saturation limit of the chemical.
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CHAPTER 2: THERMODYNAMIC AND DYNAMIC CONSIDERATIONS

After considering thermodynamics and molecular dynamics of the problem, an
amorphous nanoparticle emerges as the prime candidate to augment solubility.
2.1 Thermodynamic Considerations
Dissolution is largely a thermodynamic phenomenon. A lower energy state in
solution must coax each individual molecule from its solid bulk into a dissolved state.
Successful dislodging of molecules relies on the outward force, here the dissolution
pressure, to overwhelm the attractive forces of the solid state. These include all manner
of intermolecular forces including dipole forces or van der Waals forces. To improve both
saturation solubility and dissolution rate, these forces must reach minimum. These may
be analyzed in bulk by use of enthalpy and Gibbs ‘Free Energy.’ A solid with higher free
energy and enthalpy is expected to have more favorable thermodynamic properties,
including solubility (Hancock, Zografi 1997).
2.1.1 Solid State
The energy associated with a solid depends greatly on its solid state. Many, if not
most, solids may exist as several different polymorphs. Many of these polymorph
arrangements involve merely changing the crystal lattice arrangement. Long range order,
in general, indicates a stable state with energy sunk into the crystalline order. The
amorphous solid state describes a solid state wherein molecules exhibit no long range
7

order. This solid state has no crystal lattice; the atoms are merely jumbled together. This
solid state has the highest free energy of all solid states. Consequently it also displays the
most extreme thermodynamic properties. Figure 3 shows the Free Energy advantage of
the amorphous solid state (there called a glass) over its crystalline counterparts.

Figure 3: Characteristic Free Energy-Temperature Diagram for an Arbitrary Chemical
s

2.1.2 Amorphous Characteristics
The traditional formation of amorphous solids involves cooling. When cooled
below its freezing point, a material tends to crystallize into a solid. By preventing that
mechanism, the material enters a ‘supercooled’ liquid phase. In this phase, molecular
mobility begins to diminish along, accompanying a rising viscosity. At another critical
8

temperature, called the glass transition temperature, this viscosity spikes and the material
becomes practically frozen in a disordered state. Figure 4 shows the change in the
arrangement between an ordered crystal lattice and the jumbled, disordered amorphous
state.

Figure 4: Crystal Lattice vs. Amorphous Solid Example

In many cases, time scales of solidification interrupt the crystallization process. For
example, the rapid cooling of a melt often outpaces the crystallization process. Another
example in which we take great interest involves the rapid precipitation from solution
(Hancock, Zografi 1997).
2.1.3 Amorphous Solubility Advantage
Hancock and Parks have done extensive work in evaluating a solubility advantage
of amorphous solids. This study chose Indomethacin for detailed examination but also
9

examined several other drugs for somewhat less detailed analysis. The amorphous state
of the studied drugs were obtained via quench cooling of molten material. They were
then compared with the crystalline forms of that drug.
2.1.3.1 Theoretical
In the above referenced work, they predict the solubility advantage with a quite
simplified free energy model. Parks and co-workers (Parks 1928, 1934) developed this
model for the solubility advantage of amorphous chemicals.
𝜎

Δ𝐺 = −𝑅𝑇𝑙𝑛 ( 𝜎𝑎)
𝑐

(1)

Clearly, this model predicts that higher free energy yields a much higher solubility
ratio. This simple model approaches the amorphous solid state as a pseudo-equilibrium
solid state at all temperatures below the glass transition temperature. Since the
amorphous state has the highest possible free energy, it should also be most soluble.
Almost astonishingly, this model predicted the solubility of the amorphous chemicals to
fit anywhere from 12 to 1652 times the solubility of the crystalline form.
2.1.3.2 Experimental
The experimental data in this study aligns well qualitatively but departs
quantitatively from the free energy model. In the case of Indomethacin, the solubility
ratio was predicted between 25 and 104 but the measured solubility ratio was 4.5 at room
temperature. The dissolution profile at room temperature is presented in Figure 5.
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Figure 5: Dissolution Profile of Amorphous and Crystalline IMC at 25 Degrees Celsius

There are some important things to note about the dissolution profile in Figure 5.
First, the concentration of the crystalline substance appears to quickly rise to its saturation
limit as predicted. In the amorphous case, a sharp peak occurs to the maximum solubility
limit. The saturation then meanders down to a ‘steady state’ concentration (much less
than the peak). The presented solubility ratio refers to the drastic peak rather than the
steady condition. Even the presented solubility ratio falls far short of the predicted value.
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Figure 6: Dissolution Profile of Amorphous and Crystalline IMC at 5 Degrees Celsius

For comparison, the dissolution profile at 5℃ is presented in Figure 6. In contrast
to Figure 5, at this cooler temperature the saturation peak seems far less drastic and the
steady state condition maintains a larger solubility gap. At this cooler temperature, the
predicted solubility ratio was higher than at room temperature, stated as 38-301. The
measured solubility ratio was 4.4.
2.1.3.3 Discrepancy
The tremendous quantitative discrepancy between theoretical and experimental
data attributes to the incompleteness of the model. An explanation presented by Hancock
and Parks derives from the strong recrystallization force from a supersaturated medium.
Regardless of this precipitative trend, the qualitative solubility advantage is undeniable.
A quadrupling of solubility significantly impacts the possibility of moving a drug from a
Class II drug to a Class I drug.
12

2.2 Dynamics
The dynamics of dissolution and solubility stand on the pillars of surface area and
particle curvature. Both of these properties depend strongly on particle size and shape.
2.2.1 Surface Area
When discussing surface area, a critical step involves fixing the amount of mass.
In a pharmaceutical sense this manifests as the dosage level. It therefore becomes useful
to utilize specific surface area, or the ratio of surface area to mass. This relationship states
𝑎=

𝑆𝐴
𝑚

𝑆𝐴

= 𝜌𝑉.

(2)

Naturally, when density is held fixed this relationship becomes the ratio of surface
area to volume. If one considers a spherical particle, then this relationship may become
simplified. Hence,
𝑎∝

𝑆𝐴
𝑉

=

𝜋 2
𝑑
4
𝜋 3
𝑑
12

= 3𝑑 −1 .

(3)

Equation 3 yields the result that given a certain amount of mass to break into
spherical particles, surface area increases monotonically (and asymptotically) as diameter
shrinks.
2.2.2 Dissolution Rate
Dissolution rate experienced great growth in understanding in the early part of
the 20th century. First, Noyes and Whitney in 1897 proposed that the dissolution rate was
proportional to the difference between the concentration of the solution and the

13

saturation concentration. Brunner and Tolloczko made another leap in 1900 by proposing
that dissolution rate also scaled directly with surface area. That the dissolution rate scales
with exposed area provides a convenient method to improve the dissolution rate. Finally
Nernst and Brunner included the conclusions of Fick’s second law into the dissolution
rate in 1904, finding that dissolution rate was inversely proportional to the diffusion layer
thickness. All told, the statement of a fully evolved Noyes-Whitney equation is presented
in Equation 4.
𝑑𝑐
𝑑𝑡

=

𝐷𝑆(𝜎−𝑐)
ℎ

(4)

2.2.3 Curvature Effects
For most cases, saturation solubility is constant for a given material. This
relationship maintains validity for all sizes until a critical particle size of 1-2 𝜇𝑚 below
which saturation solubility becomes functionally dependent on size. It becomes apparent
at these small sizes that as particle size decreases, saturation solubility increases
(Junghanns and Muller 2008). The reasoning behind this phenomenon relies on the
curvature of submerged particles.
When considering the effect of curvature on solubility, important analogies must
form. According to Junghanns and Muller (2008), “The situation of a transfer of molecules
from a liquid phase (droplet) to a gas phase is in principal identical to the transfer of
molecules from a solid phase (nanocrystal) to a liquid phase (dispersion medium). The
vapor pressure is equivalent to the dissolution pressure.” With this analogy in place,
14

properties of vaporization apply analogously to dissolution. Importantly, increasing
dissolution pressure also increases equilibrium solubility.
An important relation in the world of vaporizing droplets (and in dissolving
particles) comes from the Kelvin equation, stated below. This equation demonstrates a
tremendous rate of increase in vapor pressure with radius tending to zero but relatively
small effects for relatively large radii.
2𝛾𝑉

𝑝 = 𝑝0 exp ( 𝑟𝑅𝑇𝑚 )

(5)

The Kelvin equation, coupled with the analogy between dissolution and
vaporization explains the dependence of saturation limit on particle size.

15

CHAPTER 3: ATOMIZATION AND EVAPORATION

3.1 Electrospray
Electrospray describes one method of atomizing a liquid into a field of droplets.
This method attracts interest for three primary benefits. First, electrospray produces
primary droplets which are monodisperse, or have small variation in size within the
droplet population. Second, tuning experimental parameters allows for enormous
variation in mean droplet diameters, ranging from hundreds of microns down to mere
nanometers. Finally, these desirable droplet characteristics emerge without dependence
on the initial size of the nozzle allowing for large nozzles and minimal clogging.

16

Figure 7: Left: Stable Taylor Cone and ES Shroud; Right: Schematic of Jet Breakup

The mechanism of electrospray uniquely relies on electro-hydrodynamic forces and their
interplay with surface tension. A brief overview of uncharged spray like phenomena
(hereon referred to as ballistic emission) aids the natural implementation of electrostatic
effects.
3.1.1 Ballistic Jet
Consider a hollow rigid column with an end exposed to the environment (a
nozzle) and liquid flowing toward the exposed end. One expects this liquid, once ejected
from the nozzle, to form a column of liquid on the basis of inertia (note: inertia generally
scales with density, 𝜌, and the square of velocity, v. This expectation decomposes as
17

𝑁

inertia decreases with diminishing flow rate. In fact, surface tension (𝛾, 𝑚) quickly
dominates the behavior of this liquid as inertial values decrease. The relative magnitudes
of inertial forces are compared with surface tension forces in the dimensionless Weber
number (equation 6) and frequently appears in the analysis of liquid jets, jet breakup, and
aerosol science at large.
𝑊𝑒 =

𝜌𝑣 2 𝑙
𝛾

(6)

The competition between surface tension and inertia in ballistic emission results
in two distinct modes of operation: dripping and jetting. While technical descriptions of
these modes exist, a more direct understanding evolves from example. Any household
faucet operates in the jetting mode during full use but experiences the dripping mode
during much smaller flow rates.
3.1.2 Electrospray Jet
Electrospray throws another hat in the ring of this match between inertia and
surface tension. Consider further a high voltage applied between the previously
described nozzle (with the added condition that the nozzle conduct electricity) and a
grounded plane some distance away. This high voltage creates an electric field between
the nozzle and the ground. Charge carriers within the fluid feel a force from exposure to
this field, generally directed toward the ground. This force competes directly with surface
tension forces.
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3.1.3 Solution
The above description heavily simplifies the process and serves only to yield an
intuitive understanding of the phenomenon. In fact, electrospray relies on a complex
array of factors including the precise geometry of the electric field, supplied fluid flow
rate, nozzle diameter, and especially solution properties. Among the solution properties,
some of the most critical to the process are surface tension 𝛾, viscosity 𝜇, electrical
conductivity k, and the dielectric constant 𝜀 (Almeria 2010). The rather intensive influence
on solution properties implies the necessity of appropriate planning in the production of
ink. Experimental parameters to be adjusted then become flow rate and voltage.
3.1.4 Stability
This competition results mostly in chaos; the exposed liquid rapidly oscillates
between states of surface tension and electrostatic domination. There exists a small
region of stability within the control parameters where this chaos subsides and a stable
solution emerges. This solution involves a linear drawdown in diameter of the exposed
jet until the diameter reaches some small fraction of the original diameter of the nozzle.
Once the diameter shrinks to the characteristic value, an incredibly small jet emerges. The
name ‘Taylor Cone’ refers to this stable island and represents the preferred mode of
operation for electrospray.
As previously mentioned, the Taylor Cone operates at a small island of
parameters. More practically, for a given solution, only a certain range of flow rates may
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sustain a stable cone-jet mode of emission and that Taylor Cone appears between two
voltage values. This carves a domain space out of the Flow Rate – Voltage Plane within
which we expect stable operation. This domain space changes drastically between
different solutions (on the basis of solution characteristics).
3.1.5 Droplets
The field of droplets in electrospray also exhibit interesting phenomena. The
droplets contain a charge due to the electric potential. This charge leads to interesting
divergence from the ballistic case.
Again for comparison, consider the ballistic case. If operating in a jetting mode,
then the column of liquid will propagate through the environment. The instability of this
jet causes it to decompose into a series of droplets (Rayleigh). These droplets then proceed
along their path subject only to outside forces such as gravity. Without external methods
of distributing these droplets over an area, they simply stack at their ballistic target.
The case of charged droplets diverges significantly from the ballistic case. The
small jet erupting from the tip of the Taylor Cone still decomposes into droplets as
expected. These droplets, however, are strictly bimodal and contain charge. The jet breaks
into two types of droplets: larger primary droplets and smaller satellite droplets. The
intrinsic charge in each droplet repels each other droplet by traditional Coulombic
repulsion (since they are all of like-charge). The smaller droplets feel a greater
acceleration (owing to the smaller mass) and repel to an outer shroud. The primary
20

droplets remain in the core of the droplet cloud. These primary droplets exhibit the best
monodispersity (~10% RSD). Even these primary droplets remain at the relative core of
the cloud of droplets, the electrostatic repulsion self-disperses the droplets over an area
here called the footprint of the spray.
The size of these droplets, often the defining desirable result of electrospray,
generates healthy interest. Though many models and scaling laws exist, the most
common was proposed by de la Mora and Loscertales (1994). Droplet diameter scaling
with the cube root of flow rate is the most significant takeaway, but the formula is shown
below.
1

𝑑=

𝑄𝜀𝜀 3
𝐺(𝜀) ( 𝑘 0 )

(7)

where 𝐺(𝜀) is a function of unity order.
3.1.6 Multiplexing
The impetus for multiplexing electrosprays is simple. A single cone jet operates at
flow rates of liters per year while industrial standards command liters per minute. The
only way to attain such a massive scale up while maintaining the quality of electrospray
desired lies in multiplicity. If the number of nozzles may increase without bound, then
any throughput requirement may be met. Since cost of manufacturing nozzles scales with
area manufactured, cost per nozzle naturally decreases with improved packing density
(Deng, 2009). Increasing packing density can be attained through reduction of nozzle size.
Smaller nozzle sizes minimize the amount of solvent which evaporates from the
21

meniscus, thus minimizing the cost of recovering or losing that solvent. Further,
augmented packing density improves the homogeneity of the electrospray cloud thus
improving performance per nozzle or per apparatus. Deng et al. (2006, 2009) has
demonstrated some of the best packing densities for area coverage as shown in Figure 8.

Figure 8: Multiplexing Device with Hexagonally Distributed Nozzles (Deng, 2009)

Another multiplexing method is the linear array where nozzles are not arranged
throughout an area but rather in a line. Linear packing yields cheap and compact nozzle
arrays without suffering from losses in homogeneity (Lojewski et al, 2013). This spatial
compactness is well suited for many manufacturing processes, especially the so called
roll-to-roll method where the product is in motion. This motion can effectively eliminate
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the requirement for two dimensional depositors in order to produce two dimensional
depositions.
3.2 Evaporation
When producing particles via spray drying, evaporation plays a central role. With
respect to the production of amorphous nanoparticles and the maximization of surface
area, the critical effects of evaporation are droplet lifetime and particle morphology.
3.2.1 Droplet Lifetime
Though only a simplified model of evaporation, the 𝑑2 model of droplet
evaporation suitably covers most cases of small molecule solutions. The 𝑑 2 model states
𝑑 2 (𝑡) = 𝑑02 − 𝜅𝑡.

(8)

Thus, in a droplet, the surface area decreases linearly with time. An important
consequence of this law is the droplet lifetime,
𝜏𝐷 =

𝑑02
𝜅

.

(9)

Hence, smaller droplets have much shorter lifetimes than large droplets.
3.2.2 Frustration of Crystallization
To produce an amorphous solid by precipitation out of solution, nucleation must
vastly outpace crystal growth (Mullin 2001). Further, the crystal growth rate is bounded
linearly by the supersaturation of the solvent by the Burton-Cabrera-Frank
supersaturation growth relationship. Further, the classical model of nucleation proposed
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by Volmer in 1925 yields precedent for a highly nonlinear (and accelerative) relationship
between nucleation and supersaturation. Thus as supersaturation increases, nucleation
becomes the dominant phenomenon. The degree of amorphicity relies heavily on this
supersaturation in solution. The specific relationship between the two and any
optimization which might occur is beyond this contribution. We simply conclude that as
the droplet diameter decreases (and droplet lifetime) that the metastable supersaturation
will increase thus increasing the nucleation rate relative to crystal growth. Since the
evaporation rate of solvent also effects the droplet lifetime, increasing the volatility of
solvent will also augment the nucleation rate relative to crystal growth.
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CHAPTER 4: EXPERIMENTAL APPROACH AND VALIDATION

In this contribution, we propose electrospray as a production method for
amorphous

nanoparticles

of

poorly

soluble

therapeutic

agents.

Electrospray

demonstrates necessary qualities for the process including a capacity to produce very
small droplets and flexibility to many conducting solvents. Two other properties elevate
electrospray’s alignment within the pharmaceutical field: scalability and monodispersity.
The expansion of multiplexing by Deng and others have propelled electrospray into low
cost scale up to any industrial need. Further, the uncommon property of monodispersity
dramatically increases reproducibility, minimizing batch to batch variation.
A model drug is chosen to represent many Class II drugs. A solvent which may
dissolve the model drug and fit well with electrospray forms the solution headed to
further analysis. Four properties need evaluation: size, shape, crystallinity, and solubility
profile. Scanning Electron Microscopy evaluates the morphology of the particles. X-Ray
diffraction reveals sample crystallinity. Finally, UV-Vis Spectroscopy is utilized to form
a dissolution profile (concentration over time) to evaluate a real solubility advantage.
Each of these three methods of analysis require different experimental parameters
discussed in detail below.
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4.1 Model Drug
Indomethacin (IMC), a hydrophobic and poorly water soluble drug, represents an
ideal chemical for study because literature has already explored this substance with great
zeal (Babu and Nangia 2011; Andronis et al 1996; BASF 2011; Hancock Zografi 1996; Jain
2000; Hancock and Parks, 2000; Hernandez et al, 2008; Yamamoto 2012). The chemical
structure of IMC is shown in Figure 9.

Figure 9: Molecular Structure of Indomethacin

Of course, properties of the IMC will be critical to its analysis. The relevant
properties are presented in Table 1. The indomethacin in this study was acquired from
sigma Aldrich at >99% purity.
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Table 1: Properties of Indomethacin

Indomethacin Properties
Property

Value

Unit

358 g∙mol-1

Molecular weight

0.937 mg∙L-1

Aqueous Solubility
Melting Point

438 K

Glass Transition

320 K

ρ (crystalline)

1.38 kg∙m-3

ρ (amorphous)

1.32 kg∙m-3

Absorption Peaks

260, 319 nm

4.2 Solvent choice and Solution Properties
Electing a solvent for processing presents a deal of complexity, especially when
involving electrospray. First and foremost, this solvent will need to dissolve IMC. It must
have favorable characteristics for electrospray. If those conditions are met, then things
such as cost and toxicity may influence the decision.
Indomethacin, though practically insoluble in water, shows reasonable solubility
in ethanol, the ethers, acetone, castor oil, and chlorinated solvents. Castor oil and the
chlorinated solvents tend to perform poorly as electrospray feed. Acetone and ethanol
are more polar than many of the ethers. Between acetone and ethanol, neither is
superior for electrospray. Acetone shows further promise in the production of
amorphous particles due to the high volatility of acetone. This decreases the droplet

27

lifetime. Because of this, acetone is used for the solvent in the electrospray feed. The
relevant properties of acetone are presented in Table 2.
Table 2: Properties of Acetone

Acetone Properties
Property

Value

Molecular Weight
Boiling Point

58
177.65

Vapor Pressure

24

Density

791

Vapor Density (Air=1)

2

Unit
-1

g∙mol
K
kPa

kg∙m-3
-

4.3 Experimental Procedure
First a solution of indomethacin and acetone was made. In these experiments a
solution of 1.5%wt indomethacin was used. The solution is then loaded into a 9.5 mm
diameter syringe and loaded into a Model NE-300 New Era Pump Systems Inc. syringe
pump operating at 12 V and .75A. The flow rate needs to minimize for the smallest
droplet possible. While a stable cone could not be held indefinitely at 100 microliters per
hour, 150 microliters per hour showed indefinite stability. The nozzle used was a 250 𝜇𝑚
ball tip of a ball point pen. This pen tip serves the same function as a hollow nozzle
though exhibits a larger stability island due to the viscous impedance created by the ball.
Similarly, a flat tipped hollow nozzle could have been used. The working distance
between the nozzle and substrate was chosen to be excessively large such that the
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droplets were guaranteed to fully dry by the impact time. The droplet lifetime of a 5𝜇𝑚
droplet of acetone (evaporation constant of 2 ∗
Overestimating the steady droplet speed as 10

𝑚
𝑠

2

𝑚
10−8 𝑠

) will be 𝜏𝐷 =

(5∗10−6 𝑚)
2∗10−8

2

≈ 1𝑚𝑠

, the distance a droplet should require

for full evaporation is roughly 1 cm. For these trials, a working distance of no less than 4
cm were used. The stability voltage varied for each trial, but a voltage was consistently
chosen between 1 and 10 kV. This value mostly comes as a result of the other parameters
and is set merely to achieve stability. Each experiment presents the full array of
experimental parameters which accompany that run.
4.4 Morphological Studies
Although the applicable product to the pharmaceutical industry is powder, all
samples in this study were deposited onto some substrate. For analysis under scanning
electron microscopy, samples were deposited on copper coated silicon wafers. Because
IMC may not conduct electricity, all samples underwent a sputter coat of gold and
platinum for 90 seconds. First, several single layer deposition of particles allowed for
sizing analysis of individual particles. Then, an increased exposure time sample
elucidated an interesting development.
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4.4.1 Crystalline Indomethacin
When seeing the micrographs of deposited Indomethacin, a crystalline reference
state is useful. Figure 10 shows the morphology of the crystalline indomethacin
purchased from Sigma Aldrich.

Figure 10: Micrograph of Crystalline Indomethacin
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4.4.2 Monolayer Deposition
4.4.2.1 Flow Rate Dependence
Recall that the droplet size of electrospray is proportional to the cube root of flow
rate. Because we desire small droplets, minimal flow rate is necessary. To verify the cube
root dependence, IMC was spray deposited twice: once at a flow rate of 150 microliters
per hour and once at 8 times that flow rate. The precise experimental parameters given
in Table 3.
Table 3: Experimental Parameters of a Slow Flow Rate Spray (left) and Higher Flow Rate (right)

Experimental Parameters
Solvent

Acetone

Solute

IMC

Flow Rate

0.15

Concentration

Experimental Parameters

Mw=
58
Mw=
358

Mw=
58
Mw=
358

Solvent

Acetone

Solute

IMC

mL/h

Flow Rate

1.2

mL/h

1.5

%wt

Concentration

1.5

%wt

Exposure
Time

5

min

Exposure
Time

5

min

Footprint
Diameter

6

cm

Footprint
Diameter

12

cm

Working
Distance

6

cm

Working
Distance

6

cm

Voltage

6.2

kV

Voltage

6.57

kV

Date

2/19/2014

Date

2/19/2014
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The resulting morphologies are given in Figures 11 and 12. By inspection, it is clear
that the scaling law holds generally. In this deposition, the particles are morphologically
odd in the case of smaller flow rates but more spherical in the larger flow rate case. This
modulation of morphology is not unimportant as all deviation from a sphere increases
specific surface area.

Figure 11: Micrograph of Slow Flow Rate Deposition
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Figure 12: Micrograph of Higher Flow Rate Deposition

4.4.2.2 Sizing Study
In this monolayer deposition study, the experimental apparatus deposited a
solution of IMC for a short time to gather a single layer of particles. The experimental
parameters are collected in Table 4. A flow rate of 150 microliters per hour is the smallest
flow rate that a stable cone could be generated with the experimental apparatus described
above.
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Table 4: Experimental Parameters of the Sizing Study

Experimental Parameters
Mw=
58
Mw=
358

Solvent

Acetone

Solute

IMC

Flow Rate

0.15

mL/h

Concentration

1.5

%wt

0.5

min

2.5

cm

4

cm

Voltage

4.88

kV

Date

1/7/2013

Exposure
Time
Footprint
Diameter
Working
Distance

This sample was examined under a Phenom SEM and several pictures were taken
at 7750x magnification. One such image is shown in Figure 13. The particles formed
morphologically as dimpled spheres.
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Figure 13: Micrograph of the Deposition Used for Sizing

These images were then analyzed in ImageJ image analysis software (NIH) for the
size distribution of the particles. The results from this size distribution are presented in
Table 5. Even with a reasonably high sample population, the relative standard deviation
remains below 30%.
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Table 5 Resutls of the Sizing Study

Results
Number Average
St. Dev
of
Diameter
(micron)
Particles (micron)
516

0.64

0.18

4.4.3 Multilayer Deposition
In later trials, a larger volume than a single layer becomes necessary for analysis.
To gauge the type of matrix formed by layers of these particles, low weight solution of
IMC in acetone was spray deposited for an extended time span. The experimental
parameters for this specific deposition are shown in Table 6.
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Table 6: Experimental Parameters of a multilayer deposition

Experimental Parameters
Mw=
58
Mw=
358

Solvent

Acetone

Solute

IMC

Flow Rate

0.15

mL/h

Concentration

1.5

%wt

120

min

6

cm

Voltage

6.03

kV

Date

1/3/2014

Exposure
Time
Working
Distance

Figure 14 shows the resulting particle matrix. Interestingly, the powder does not
appear as a stack of spheres as one would expect of a powder, but rather an
interconnected matrix with some degree of continuity. The matrix still tends to bulge as
if retaining memory of its constituent particles but does not appear to be dispersed. That
being said, the branches apparent in Figure 14 are of characteristic length consistent with
the sizing study; the thicker bulges average in the 700 nanometer range with a tolerance
of roughly 200 nanometers. The ‘necked’ narrower regions may reach dimension as small
as 100 nm.
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Figure 14: Micrograph of Layered Depostion

4.5 Crystallinity Evaluation
To evaluate the amorphicity of the deposited indomethacin, X-Ray Diffraction will
be used. Deposited particles only reach thicknesses <10 𝜇𝑚 during reasonable
experimental time scales, so Thin Film X-Ray Diffraction is utilized for evaluation.
4.5.1 Literature
Hernandez et. al. performed X-Ray Diffraction on two different polymorphs of
Indomethacin as well as the amorphous state. A Siemens Kristalloflex 5000 diffractometer
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was used. Their data are presented in Figure 15. Curve C represents the diffraction
pattern of the 𝛾 crystal, curve B shows the 𝛼 crystal, and curve A is amorphous.

Figure 15: X Ray Diffraction of Indomethacin in Various Forms from Literature

4.5.2 Experimental
For crystallinity evaluation of electrospray deposited particles, X-ray diffraction
was performed on a Rigaku D/MAX XRD with a 40kV Copper X-ray tube, 2 Theta
Goiniometer, Datascan 4 Acquisition Software, and a thin film diffraction attachment.
Both a crystalline sample and amorphous sample were analyzed. Figure 16 shows both
curves gathered on the same axes. 2𝜃 spanned 10-40 degrees. The incident angle was held
constant at 5 degrees. Because IMC is an organic molecule, diffraction is expected only at
lower angles; this is supported by literature (Hernadez et al).
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The diffracted sample used the standard solution of this study (1.5%wt, .15 mL/h)
with a sample exposure time of 60 minutes. This elongated exposure time allows the
sample to obtain a sufficiently thick coating for analysis. At this time, the thickness of the
film is underestimated to be on the order of the diameter of the particles. This guarantees
at least a monolayer thickness, particularly at the core of the spray. Figure 16 shows the
diffraction data of the amorphous sample (quite flat and blue) superposed over the
diffraction data for the crystalline powder (substantially higher peaks and red).

Figure 16: Experimental X-ray Diffraction of Amorphous and Crystalline IMC

The data demonstrates strong agreement with literature. We conclude that spray dried
IMC lacks crystalline structure, as predicted.
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4.5.3 Extra Evidence of Amorphicity
As discussed above, the amorphous state is a thermodynamically unstable solid
form. It exhibits great molecular mobility and given time will change quite drastically,
especially if stored under stressful conditions. The changes which occur center strongly
around reverting to a crystalline form. In an attempt to understand this reversion to a
crystalline form, a sample of sprayed indomethacin was aged for 5 weeks in a nitrogen
environment. The sample was stored at room temperature which stresses the solid by
being within 50℃ of its glass transition temperature (Newman 2010). The experimental
parameters of the deposition are presented in table 7.
Table 7: Aging Study Experimental Parameters

Experimental Parameters
Mw=
58
Mw=
358

Solvent

Acetone

Solute

IMC

Flow Rate

0.15

mL/h

Concentration

1.5

%wt

Exposure
Time

60

min

Footprint
Diameter

3

cm

Working
Distance

4

cm

Voltage

7

kV

Date

12/20/2013

The resulting micrographs of this study are quite striking with respect to the
growth and propagation of crystal in an aging amorphous sample. Figure 17 shows an
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example of how crystals propagate through an amorphous sample. It also starkly
demonstrates the difference in appearance between the sprayed sample (top middle)
and crystalline indomethacin (the rest).

Figure 17: Crystal propagation over aged sample

Figure 18 shows a detail of the boundary between crystal and amorphous
indomethacin in the aged sample
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Figure 18: Crystal Propagation detail

The most striking aspect of this micrograph is how amazingly sharp the boundary
appears between crystal and amorphous sample. We conclude this is due to a
propagation of crystal like a wave through the sample. Initially, crystalline seeds nucleate
spontaneously from the amorphous solid and then grow at the boundaries of the
amorphous state around it. Figure 19 shows an example of a spontaneously developed
crystalline seed.
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Figure 19: Crystalline seed nucleated from amorphous solid

Because the sample seems to have deteriorated over time to a crystal form, the
sample must have started without crystal structure. These aging studies support the
diffraction data.
4.6 Solubility Advantage Verification
Solubility data are obtained with UV-Vis spectrophotometry in coordination with
Beer’s Law. Explorations seek to evaluate the dissolution profile of sprayed indomethacin
against crystalline indomethacin. This dissolution profile is then compared to the
dissolution profile obtained by Hancock and Parks.
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4.6.1 Beers Law
Beer’s law expresses the relationship between concentration in solution and
absorbance. The explicit statement of Beer’s law is stated as
𝐴 = 𝜖𝑏𝑐.

(10)

It relates absorbance, defined as
𝑃

𝐴 = log10 𝑃0 ,

(11)

to the molar absorptivity, optical path length, and concentration of solute.
This simple relationship allows the calculation of concentration of a substance in
solution given a fixed path length and known molar absorptivity. Because molar
absorptivity depends functionally on wavelength, Beer’s law is most appropriately
applied at a specific wavelength.
4.6.2 UV Vis Spectrophotometry
A spectrophotometer measures the amount of light a sample absorbs. The device
releases a luminous pulse of known intensity through a sample solution and measures
the intensity of the light after it leaves the sample. Recalling the definition of absorbance,
a decreasing measured intensity clearly accompanies an increasing absorbance.
UV-Vis Spectrophotometry describes a spectrophotometer which operates
between the ultraviolet and visual spectra. This type of spectrophotometer is necessary
for the analysis of IMC since the ‘spectral peaks’ of indomethacin occur at 230, 260, and
318 nm which all occur within that range.
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4.6.3 Experimental
UV-Vis spectrophotometry, coupled with Beer’s law and cuvettes of known
optical path length, allows the evaluation of the dissolution profile of spray deposited
indomethacin and a crystalline standard. In order to test the dissolution profile, an excess
of amorphous sample dissolves into deionized water. Samples are taken periodically as
the dissolution proceeds and subjected to spectrophotometry.
In this study, the excess of amorphous sample was determined to be two hours of
deposition (roughly three milligrams) in a 50 mL volume of deionized water. Since the
saturation solubility of crystalline indomethacin is roughly 1 mg/L, this volume
represents a potential 30 fold supersaturation. Since this value could never actualize, it
represents an ‘excess’. Samples (after the blank sample) were taken every 6 minutes with
the first sample being taken 3 minutes after the addition of solute. Similarly, the control
study used 3 mg of crystalline IMC (Sigma Aldrich) in 50 mL of de ionized water with
samples being taken identically to the amorphous group.
The sample group and control constituted 50 spectral analyses total. The strongest
response came from the spectral peak at 260 nm. The value of absorbance at 260 nm was
isolated from each spectrum and compiled in a table, paired with its corresponding time.
The constant of proportionality (necessitated by Beer’s law) was evaluated via the known
value of saturation for crystalline indomethacin (.937 mg/L) along with the averaged
value of the control sample absorbance. This gave a constant of proportionality as .474
L/mg. After transforming the absorbance data into concentration data, the two data sets
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(amorphous and control) were superposed over their identical time scales. The results are
presented in Figure 20.

Dissolution Profile of Amorphous and
Crystalline Indomethacin in DI Water
(analyzed at 260 nm)
1.8000

Concentration (mg/L)

1.6000
1.4000
1.2000
1.0000
0.8000
0.6000
0.4000
0.2000
0.0000
0

20

40

60

80

100

Time (min)
Amorphous

Crystalline

Figure 20: Dissolution Study Results

These results are consistent with data taken from the 318 nm spectral peak, but
this profile is omitted due to redundancy. We predict the stark variation and apparent
instability in crystalline data derives from sample present concentration gradients and
perhaps insufficient mixing. It would seem that the amorphous sample avoided the same
problems but the nature of this unpredictable variation in the control is beyond the scope
of this investigation. Clearly, the steady state concentration of the amorphous
nanoparticles far exceeds that of the crystalline control. In fact, the steady value delivers
an 88.5% improvement over the solubility of powdered crystal. It is interesting to note
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that the profile of sprayed IMC, though conducted at room temperature, bears a much
closer resemblance to the Hancock and Parks amorphous indomethacin dissolution test
conducted at 5℃ than the test conducted at 25℃. We do not speculate towards reasons
or mechanisms for this but observe that the spring is less violent and the parachute
substantially more gentle.
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CHAPTER 5: CONCLUSIONS

We conclude that electrospray represents an high potential emerging method for
the production of amorphous nanoparticles. Electrospray succeeded in producing
particles of submicron diameter and aspherical morphology with high monodispersity.
These particles evaporated quickly enough to exhibit high amorphicity as well as a
substantial aqueous solubility advantage. Coupled with the potential for scale up to
industrial throughputs, electrospray presents a strong case for feasible powder
production of active pharmaceutical ingredients. Though the particles in this study were
deposited on a silicon substrate, the ultimate goal is a powder for pharmaceuticals. This,
however, is work which has already been accomplished for other spray drying
techniques with cyclone technology.
Other work in post processing involves the solid solution of drug particles
with various polymer excipients. The same principles presented in this study apply
equally to those efforts. The primary challenge in those explorations is the complexity of
the solution. Each case is unique and requires special care. After the solution properties
are resolved appropriately, then everything remains practically identical.
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